CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price fell 2% during mid-day trading on Wednesday . The stock traded as low as $2.01 and last traded at $2.01. 34,299 shares traded hands during trading, a decline of 27% from the average session volume of 46,949 shares. The stock had previously closed at $2.05.
Wall Street Analysts Forecast Growth
Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of CytoMed Therapeutics in a report on Tuesday, June 11th.
Read Our Latest Analysis on CytoMed Therapeutics
CytoMed Therapeutics Trading Down 8.1 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is the Hang Seng index?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.